When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
DBVT - Aimmune Therapeutics: A Catalyst-Driven Buy Before Advisory Committee Meeting
DBV Technologies S.A.
We haven't covered Aimmune Therapeutics, Inc. (AIMT) as much as we should, barring an article comparing Aimmune and its distant competitor DBV Technologies (DBVT), where we said that AIMT is probably the better investment. Late last year, after DBVT withdrew its US marketing application for its Viaskin product targeting peanut allergy, AIMT spiked overnight, especially after filing its own NDA/BLA for AR101 in peanut allergy. However, problems at the FDA having to do with politics delayed the approval and took the stock down and kept it subdued. Lately, though, we are